Navigation Links
MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering
Date:10/5/2007

MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that it has priced its initial public offering of 5,000,000 shares of common stock at a price of $12.00 per share. All shares are being offered by MAP Pharmaceuticals. In addition, MAP Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares to cover over-allotments, if any. Merrill Lynch & Co. and Morgan Stanley & Co. Incorporated are joint book-running managers for the offering and Deutsche Bank Securities Inc. is co-lead manager for the offering. MAP Pharmaceuticals' common stock will trade on the NASDAQ Global Market under the symbol "MAPP."

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 4, 2007. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 or Morgan Stanley, Prospectus Department, 1585 Broadway, New York, New York 10036.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition Corporation ( ... just released version 9.0 of the Cognition Cockpit platform. , “Our whole team ... David Cronin, CEO of Cognition. “We’re thrilled to finally be able to release ...
(Date:5/18/2017)... ... 2017 , ... HOLLOWAY AMERICA, a leading manufacturer of stainless ... and pharmaceutical/biotech, recently introduced The Revolution Lift™, a new precision-controlled head lift assembly ... comes on the heels of HOLLOWAY’s release of the intelliVessel™, a smart tank ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated neurological ... to develop Alzheimer’s disease, while men are at greater risk for Parkinson’s disease. ... bias is the aim of a research program at Worcester Polytechnic Institute (WPI) ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):